Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis

Inclusion Criteria: * Patients with diagnosis of seasonal or perennial allergic conjunctivitis. * Age ≥ 6 years old at screening visit. * Male or female patients. Applicable in patients ≥ 18 years old. * Patient has signed the Informed Consent Form (ICF) prior to any screening procedures. Applicable in patients with age ≤ 18 years old. * Patients Patients'parents or legal guardians signed an Informed Consent Form (ICF). * The patients also provided written assent. Exclusion Criteria: * Presence of any form of allergic conjunctivitis other than seasonal or perennial allergic conjunctivitis (Atopic keratoconjunctivitis, giant papillary conjunctivitis). * Any other ophthalmic medication within seven days prior to randomization. * Patient with one blind eye. * Visual acuity of 20/40 in any eye. * Patients with history of active stage of any other concomitant ocular disease. * Contraindications or sensitivity to any component of the study treatments. * Contact lens users. * Ocular surgery within the past 3 months. * Women who were not using an effective means of contraception or who were pregnant or nursing. * Participation in any studies of investigational drugs within 90 days previous to the inclusion. Discontinuation criteria: * Patients could be discontinued before the completion of the study because of use of prohibited medications, adverse events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.